Method, composition and device for treating starch related diseases

Abstract

The present invention includes a method of diagnosing an insulin resistant mammal including the steps of obtaining one or more samples for testing; and determining the level of starch in the one or more samples, whereby the presence of starch correlates with insulin resistant.

1 . A method of diagnosing an insulin resistant mammal comprising the steps of: 
 obtaining one or more samples for testing; and    determining the level of starch in the one or more samples, whereby the presence of starch correlates with insulin resistant.    
   
   
       2 . The method of  claim 1 , wherein the step of testing further comprises contacting the one or more samples with one or more bicarbonates, one or more alkaline agents, one or more hexokinases, one or more oxidases, one or more amylases or combination thereof.  
   
   
       3 . The method of  claim 1 , wherein the step of testing includes detecting one or more visible wavelengths, one or more IR wavelengths, one or more Near IR wavelengths, one or more UV wavelengths, one or more fluorescence wavelengths, one or more chemiluminescence wavelengths, one or more radiation emissions, one or more FRET emissions, one or more ELISA emissions or combination thereof.  
   
   
       4 . The method of  claim 1 , wherein the one or more samples are blood, sweat, tears, urine, saliva, cellular fluids, mucus tissues, skin, organs or combination thereof.  
   
   
       5 . A method of detecting a polysaccharide-based disease comprising the steps of: 
 isolating a sample from a patient suspected of having the polysaccharide based disease; and    determining the relative level of polysaccharide in the sample.    
   
   
       6 . The method of  claim 5 , wherein the step of determining the relative level of polysaccharide in the sample comprises the detection of one or more visible wavelengths, one or more IR wavelengths, one or more Near IR wavelengths, one or more UV wavelengths, one or more fluorescence wavelengths, one or more chemiluminescence wavelengths, one or more radiation emissions, one or more FRET emissions, one or more ELISA emissions or combination thereof.  
   
   
       7 . A method of treating an insulin resistant patient comprising the step of: 
 isolating a sample from a patient suspected of having the polysaccharide based disease;    determining the relative level of polysaccharide in the sample; and    administering a pharmaceutical formulation to the patient one or more hexokinases, one or more oxidases, one or more amylases or combination thereof.    
   
   
       8 . The method of  claim 7 , wherein the pharmaceutical formulation comprises one or more enzymes, one or more compounds, one or more solutions, one or more vitamins, one or more minerals or combinations thereof.  
   
   
       9 . The method of  claim 7 , wherein the pharmaceutical formulation comprises one or more bicarbonates, one or more alkaline agents, one or more hexokinases, one or more oxidases, one or more amylases or combination thereof.  
   
   
       10 . The method of  claim 7 , wherein the pharmaceutical formulation is an intravenous preparation, a capsule, a tablet, a medicinal syrup, a liquid, a lotion, a spray, an ointment, a cream, a dissolvable tablet, a suppository, an effervescent tablet or combination thereof.  
   
   
       11 . A diagnostic device comprising: 
 a sensor that measures the presence of one or more polysaccharides, wherein the sensor contacts a sample suspected of having polysaccharides present.    
   
   
       12 . The diagnostic device of  claim 11 , wherein the sensor detects one or more visible wavelengths, one or more IR wavelengths, one or more Near IR wavelengths, one or more UV wavelengths, one or more fluorescence wavelengths, one or more chemiluminescence wavelengths, one or more radiation emissions, one or more FRET emissions, one or more ELISA emissions or combination thereof.  
   
   
       13 . The diagnostic device of  claim 11 , wherein the sample is combined with one or more bicarbonates, one or more hexokinases, one or more oxidases, one or more amylases or combination thereof.  
   
   
       14 . A method of determining the total sample disaccharide/monosaccharide levels in a patient comprising the step of: 
 detecting an initial disaccharide/monosaccharide level in a sample;    converting one or more oligosaccharides in the sample into one or more monosaccharides; and    detecting a total disaccharide/monosaccharide level in a sample, whereby the difference between the initial disaccharide/monosaccharide level and the total monosaccharide level is the level of polysaccharides in the sample.    
   
   
       15 . The method of  claim 14 , wherein the step of converting one or more oligosaccharides to one or more disaccharides or monosaccharides comprises adding one or more bicarbonates, one or more hexokinases, one or more oxidases, one or more amylases or combination thereof to the sample.  
   
   
       16 . An pharmaceutical formulation in a dosage form for effectively decreasing polysaccharide levels comprising: 
 one or more agents capable of converting polysaccharides into disaccharides/monosaccharides.    
   
   
       17 . The pharmaceutical formulation of  claim 16 , wherein the pharmaceutical formulation is an intaravenous preparation, a capsule, a tablet, a medicinal syrup, a liquid, a lotion, a spray, an ointment, a cream, a dissolvable tablet, a suppository, an effervescent tablet or combination thereof.  
   
   
       18 . The pharmaceutical formulation of  claim 16 , wherein the one or more agents comprise one or more bicarbonates, one or more alkaline agents, one or more hexokinases, one or more oxidases, one or more amylases or combination thereof.  
   
   
       20 . A method of determining a starch level of an individual comprising the steps of: 
 applying a reaction solution to a portion of the skin of the individual; and    determining the starch level in the skin with a sensor that measures the product of the reaction solution on the skin.    
   
   
       21 . The diagnostic device of  claim 20 , wherein the sensor detects one or more visible wavelengths, one or more IR wavelengths, one or more Near IR wavelengths, one or more UV wavelengths, one or more fluorescence wavelengths, one or more chemiluminescence wavelengths, one or more radiation emissions, one or more FRET emissions, one or more ELISA emissions or combination thereof.  
   
   
       22 . The method of  claim 20 , wherein the reaction solution comprises: iodine, water, an alcohol and a salt.  
   
   
       23 . The method of  claim 20 , wherein the sensor is portable.  
   
   
       24 . An enzyme in a dosage form for effectively decreasing polysaccharide levels, comprising: 
 a therapeutically effective amount of one or more enzymes capable of converting polysaccharides into disaccharides and/or monosaccharides; and    one or more pharmaceutical agents.    
   
   
       25 . The enzyme in a dosage form of  claim 24 , wherein the one or more enzymes are blended with one or more agents.  
   
   
       26 . The enzyme in a dosage form of  claim 24 , wherein the one or more enzymes are one or more hexokinases, one or more oxidases, one or more amylases or combination thereof.